Park Y - Search Results

1

A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity.

Lee DH, Ahn H, Sim HI, Choi E, Choi S, Jo Y, Yun B, Song HK, Oh SJ, Denda-Nagai K, Park CS, Irimura T, Park Y, Jin HS. Lee DH, et al. Among authors: park cs, park y. J Exp Clin Cancer Res. 2023 Oct 20;42(1):272. doi: 10.1186/s13046-023-02840-9. J Exp Clin Cancer Res. 2023. PMID: 37858248 Free PMC article.

2

CD226^hiCD8⁺ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy.

Jin HS, Ko M, Choi DS, Kim JH, Lee DH, Kang SH, Kim I, Lee HJ, Choi EK, Kim KP, Yoo C, Park Y. Jin HS, et al. Among authors: park y. Cancer Immunol Res. 2020 Jul;8(7):912-925. doi: 10.1158/2326-6066.CIR-19-0877. Epub 2020 Apr 7. Cancer Immunol Res. 2020. PMID: 32265229

3

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.

Jin HS, Park Y. Jin HS, et al. Among authors: park y. BMB Rep. 2021 Jan;54(1):2-11. doi: 10.5483/BMBRep.2021.54.1.229. BMB Rep. 2021. PMID: 33298247 Free PMC article. Review.

4

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.

Yeo J, Ko M, Lee DH, Park Y, Jin HS. Yeo J, et al. Among authors: park y. Pharmaceuticals (Basel). 2021 Feb 28;14(3):200. doi: 10.3390/ph14030200. Pharmaceuticals (Basel). 2021. PMID: 33670993 Free PMC article. Review.

5

Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells.

Lee DH, Kang SH, Choi DS, Ko M, Choi E, Ahn H, Min H, Oh SJ, Lee MS, Park Y, Jin HS. Lee DH, et al. Among authors: park y. Cancer Lett. 2021 Jul 10;510:37-47. doi: 10.1016/j.canlet.2021.04.006. Epub 2021 Apr 16. Cancer Lett. 2021. PMID: 33872695

6

Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy.

Lee DH, Choi S, Park Y, Jin HS. Lee DH, et al. Among authors: park y. Pharmaceuticals (Basel). 2021 Oct 17;14(10):1053. doi: 10.3390/ph14101053. Pharmaceuticals (Basel). 2021. PMID: 34681277 Free PMC article. Review.

7

PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.

Lee DH, Jeong YJ, Won JY, Sim HI, Park Y, Jin HS. Lee DH, et al. Among authors: park y. Biomedicines. 2022 Jan 27;10(2):299. doi: 10.3390/biomedicines10020299. Biomedicines. 2022. PMID: 35203508 Free PMC article.

8

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.

Sung E, Ko M, Won JY, Jo Y, Park E, Kim H, Choi E, Jung UJ, Jeon J, Kim Y, Ahn H, Choi DS, Choi S, Hong Y, Park H, Lee H, Son YG, Park K, Won J, Oh SJ, Lee S, Kim KP, Yoo C, Song HK, Jin HS, Jung J, Park Y. Sung E, et al. Among authors: park e, park y, park h, park k. Mol Ther. 2022 Aug 3;30(8):2800-2816. doi: 10.1016/j.ymthe.2022.05.003. Epub 2022 May 6. Mol Ther. 2022. PMID: 35526096 Free PMC article.

9

Extracellular pH modulating injectable gel for enhancing immune checkpoint inhibitor therapy.

Jin HS, Choi DS, Ko M, Kim D, Lee DH, Lee S, Lee AY, Kang SG, Kim SH, Jung Y, Jeong Y, Chung JJ, Park Y. Jin HS, et al. Among authors: park y. J Control Release. 2019 Dec 10;315:65-75. doi: 10.1016/j.jconrel.2019.10.041. Epub 2019 Oct 25. J Control Release. 2019. PMID: 31669264 Free article.

10

Enhancing adoptive T-cell therapy with fucoidan-based IL-2 delivery microcapsules.

Jeon EY, Choi DS, Choi S, Won JY, Jo Y, Kim HB, Jung Y, Shin SC, Min H, Choi HW, Lee MS, Park Y, Chung JJ, Jin HS. Jeon EY, et al. Among authors: park y. Bioeng Transl Med. 2022 Jul 5;8(1):e10362. doi: 10.1002/btm2.10362. eCollection 2023 Jan. Bioeng Transl Med. 2022. PMID: 36684086 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25,917 results

Search Page